obesity

News

Wegovy sales double, as starting restrictions start to lift

Novo Nordisk’s breakneck sales growth has continued in the first quarter of this year with a 24% increase that was helped by a doubling in turnover of obesity blockbuster Wegovy

Market Access

Weight loss treatments bring in billions but capacity remain...

The high demand for weight loss treatments has made their rollout a staggered process.

Patients

Our expanding toolbox: Designing personalised strategies in ...

When I began practicing obesity medicine nearly 20 years ago, it was difficult for my patients to attain significant long-term weight loss without metabolic and bariatric surgery.

News

Metsera lands with $290m to take on obesity giants

Any company hoping to make headway in the market for obesity therapies will need deep pockets, so it’s an encouraging sign that start-up Metsera has launched with an impre

News

Trials set up filing for Lilly’s tirzepatide in sleep apnoea

Eli Lilly’s diabetes and obesity therapy tirzepatide could find a use as a treatment for obstructive sleep apnoea (OSA) after hitting the mark in a pair of phase 3 trials.

News

EMA finds no suicide risk with GLP-1 diabetes, obesity drugs

There is no evidence of an increased risk of suicidal or self-injurious thoughts and actions with GLP-1 agonists used to treat diabetes and obesity, according to the EU me

Wegovy sales double, as starting restrictions start to lift

Weight loss treatments bring in billions but capacity remain...

Our expanding toolbox: Designing personalised strategies in ...

Metsera lands with $290m to take on obesity giants

Trials set up filing for Lilly’s tirzepatide in sleep apnoea

EMA finds no suicide risk with GLP-1 diabetes, obesity drugs

Ambrosia's sweet $100m round, and other biofinancings

Using AI-driven synthetic personas to take your insights fur...

obesity

Editor's Picks